These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 22914469)
1. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Sprague BL; Trentham-Dietz A; Cronin KA Obstet Gynecol; 2012 Sep; 120(3):595-603. PubMed ID: 22914469 [TBL] [Abstract][Full Text] [Related]
2. Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Jewett PI; Gangnon RE; Trentham-Dietz A; Sprague BL Obstet Gynecol; 2014 Oct; 124(4):727-733. PubMed ID: 25198271 [TBL] [Abstract][Full Text] [Related]
3. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Hing E; Brett KM Obstet Gynecol; 2006 Jul; 108(1):33-40. PubMed ID: 16816053 [TBL] [Abstract][Full Text] [Related]
4. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study. Du Y; Scheidt-Nave C; Schaffrath Rosario A; Ellert U; Dören M; Knopf H Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194 [TBL] [Abstract][Full Text] [Related]
5. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929 [TBL] [Abstract][Full Text] [Related]
6. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108 [TBL] [Abstract][Full Text] [Related]
7. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. Hersh AL; Stefanick ML; Stafford RS JAMA; 2004 Jan; 291(1):47-53. PubMed ID: 14709575 [TBL] [Abstract][Full Text] [Related]
8. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Haas JS; Kaplan CP; Gerstenberger EP; Kerlikowske K Ann Intern Med; 2004 Feb; 140(3):184-8. PubMed ID: 14757616 [TBL] [Abstract][Full Text] [Related]
9. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Speroff L Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199 [TBL] [Abstract][Full Text] [Related]
10. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials. Perez MV; Wang PJ; Larson JC; Virnig BA; Cochrane B; Curb JD; Klein L; Manson JE; Martin LW; Robinson J; Wassertheil-Smoller S; Stefanick ML Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1108-16. PubMed ID: 23169946 [TBL] [Abstract][Full Text] [Related]
11. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D; JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113 [TBL] [Abstract][Full Text] [Related]
12. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Barry MJ; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Krist AH; Kurth AE; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW JAMA; 2017 Dec; 318(22):2224-2233. PubMed ID: 29234814 [TBL] [Abstract][Full Text] [Related]
13. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Stefanick ML Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329 [TBL] [Abstract][Full Text] [Related]
15. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Steinkellner AR; Denison SE; Eldridge SL; Lenzi LL; Chen W; Bowlin SJ Menopause; 2012 Jun; 19(6):616-21. PubMed ID: 22648302 [TBL] [Abstract][Full Text] [Related]
16. Health behaviors and other characteristics of women on hormone therapy: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Brennan RM; Crespo CJ; Wactawski-Wende J Menopause; 2004; 11(5):536-42. PubMed ID: 15356406 [TBL] [Abstract][Full Text] [Related]
17. Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. The PEPI Investigators. Greendale GA; James MK; Espeland MA; Barrett-Connor E Am J Epidemiol; 1997 Nov; 146(9):763-70. PubMed ID: 9366624 [TBL] [Abstract][Full Text] [Related]
18. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161 [TBL] [Abstract][Full Text] [Related]
19. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. Wei F; Miglioretti DL; Connelly MT; Andrade SE; Newton KM; Hartsfield CL; Chan KA; Buist DS J Natl Cancer Inst Monogr; 2005; (35):106-12. PubMed ID: 16287895 [TBL] [Abstract][Full Text] [Related]
20. The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988-1994. Friedman-Koss D; Crespo CJ; Bellantoni MF; Andersen RE Menopause; 2002; 9(4):264-72. PubMed ID: 12082362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]